Multidisciplinary Team IntervenTion in CArdio-ONcology (TITAN Study)
Conditions
Breast Cancer - Lymphoma
Conditions: Keywords
multidisciplinary team, exercise, nutrition, cardiology, physiotherapy, imaging
Study Type
Interventional
Study Phase
Phase 2
Study Design
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Intervention
Name: Multidisciplinary team intervention
Type: Behavioral
Overall Status
Recruiting
Summary
People with breast cancer and lymphoma often experience many short and long-term side effects as a result of both the cancer and the necessary treatments.

Receiving extra assessments and care from teams of multiple health professionals has been shown to be helpful for people with other health problems, such as heart disease. These 'multidisciplinary' teams may include nurses, doctors, pharmacists, dietitians, exercise therapists, counselors, and other specialists. Currently, the investigators do not know if receiving extra assessments from a multidisciplinary team is helpful for people receiving cancer treatment.

In this study, the investigators hope to learn the effect of extra assessments and early interventions from teams of health care professionals in people diagnosed with cancer, during and after the treatment period.

After initial assessments, participants will be randomized to multidisciplinary team intervention or usual care.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- histologically confirmed malignancy (breast or lymphoma);

- scheduled to receive anthracycline and/or trastuzumab-based chemotherapy;

- age ≥ 18 years;

- willing to attend follow-up visits.

Exclusion Criteria:

- physical disability preventing exercise testing or DEXA scan;

- psychiatric disease or disorder precluding informed consent;

- participation in other cardiotoxicity or exercise intervention study;

- contraindication to anti-cancer therapy, including known heart failure, cardiomyopathy, or baseline LVEF < 50%;

- previous anthracycline or trastuzumab-based therapy;

- previous radiotherapy to thorax.
Location
Cross Cancer Institute
Edmonton, Alberta, Canada
Status: Recruiting
Start Date
May 2014
Completion Date
May 2018
Sponsors
University of Alberta
Source
University of Alberta
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page